CompletedInterventionalNot ApplicableUpdated May 17, 2021
Compassionate Use of Evinacumab | NCT06500598 | Trialant
Approved for marketingExpanded AccessUpdated Oct 28, 2025
Compassionate Use of Evinacumab
ClinicalTrials.gov ID
NCT06500598
Lead Sponsor
Regeneron PharmaceuticalsINDUSTRY
Overall Status
Approved for marketing
Study Type
Expanded Access
Last Update Posted
Oct 28, 2025Actual
Brief Summary
Provide compassionate use of evinacumab
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.